ஃப்ரெடரிக் போஉலிஓத் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃப்ரெடரிக் போஉலிஓத். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃப்ரெடரிக் போஉலிஓத் Today - Breaking & Trending Today

EAU 2021: Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Is Only a Tessera in the Treatment of CRPC

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting


Press release content from Business Wire. The AP news staff was not involved in its creation.
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
February 4, 2021 GMT
NORTH BILLERICA, Mass. (BUSINESS WIRE) Feb 4, 2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021. Two of the abstracts relate to PyL™, the Company’s PET/CT imaging agent for prostate cancer, and the third ....

New York , United States , Memorial Sloan Kettering Cancer Center , New Jersey , North Billerica , Jeremyc Durack , Frederic Pouliot , Mark Kinarney , Oliver Sartor , Bausch Health Companies Inc , Centre Hospitalier Universitaire , Progenics Pharmaceuticals Inc , Tulane Cancer Center , Lantheus Medical Imaging Inc , Corporate Communications , Lantheus Holdings Inc , Lantheus Medical Imaging , Progenics Pharmaceuticals , Clinical Oncology Genitourinary , Virtual Meeting , Poster Session , Prostate Cancer , Advanced Disease , Progress Poster Session , Advanced Prostate Cancer , Lantheus Holdings ,

ASCO GU 2020: PSMA-targeted 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer (OSPREY)


ASCO GU 2020: PSMA-targeted 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer (OSPREY)
San Francisco, California (UroToday.com) In this oral abstract, the author presented results from Cohort A of the OSPREY trial (NCT02981368) looking at the diagnostic performance of the PSMA-PET radiopharmaceutical 18F-DCFPyL in 252 high-risk prostate cancer patients who are to undergo radical prostatectomy with lymphadenectomy. This tracer is owned by Progenics Pharmaceuticals, Inc, and is similar to other PSMA-PET radiopharmaceuticals available such as 68Ga (Gallium-68), though the 18F radioisotope may have favorable nuclear decay properties.
PSMA is a transmembrane glycoprotein that is expressed in primary and metastatic prostate adenocarcinoma, but not neuroendocrine carcinoma. Utilizing the PSMA protein in PET/CT prostate diagnosis is of interest given the limited utility of conventional 18F-FDG PET/CT. Available data suggests that PSMA targeting PET imaging may perform b ....

United States , San Francisco , Alok Tewari , Frederic Pouliot , Urology Division , Progenics Pharmaceuticals Inc , Dana Farber Cancer Institute , Laval University Hospital Center , Department Of Surgery , Progenics Pharmaceuticals , Assistant Professor , Medical Oncology Fellow , Cancers Symposium , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , அலோக் திவாரி , ஃப்ரெடரிக் போஉலிஓத் , சிறுநீரகம் பிரிவு , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , லாவள் பல்கலைக்கழகம் மருத்துவமனை மையம் , துறை ஆஃப் அறுவை சிகிச்சை , உதவியாளர் ப்ரொஃபெஸர் , மருத்துவ புற்றுநோயியல் சக , புற்றுநோய்கள் சிம்போசியம் ,